Shots:

• Secure Bio to get WW commercialization rights for Farydak (panobinostat) from Novartis to treat patients with r/r multiple myeloma with no prior treatment
• The focus of the acquisition is to expand Secura Bio’s oncology portfolio and develop new product combinations for Farydak
• Farydak (panobinostat- PO) is a histone deacetylase (HDAC) inhibitor & decreases the growth of myeloma cells. On February 23 & August 28- 2015- it has received the FDA’s accelerated approval & EU’s approval for the same indication and is marketed in 53 countries

Ref: PRNewswire | Image: Secura Bio